Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Cole B Hirschfeld, Leslee J Shaw, Michelle C Williams, Ryan Lahey, Todd C Villines, Sharmila Dorbala, Andrew D Choi, Nishant R Shah, David A Bluemke, Daniel S Berman, Ron Blankstein, Maros Ferencik, Jagat Narula, David Winchester, Eli Malkovskiy, Benjamin Goebel, Michael J Randazzo, Juan Lopez-Mattei, Purvi Parwani, Joao V Vitola, Rodrigo J Cerci, Nathan Better, Paolo Raggi, Bin Lu, Vladimir Sergienko, Valentin Sinitsyn, Takashi Kudo, Bjarne Linde Nørgaard, Pál Maurovich-Horvat, Yosef A Cohen, Thomas NB Pascual, Yaroslav Pynda, Maurizio Dondi, Diana Paez, Andrew J Einstein
2021-09-01
Abstract:Objectives This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-U.S. institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and …
What problem does this paper attempt to address?